Shaanxi Meibang Pharmaceutical Group Co Ltd
Shaanxi Meibang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, sale, and agricultural technology promotion, and service of pesticide products in China and internationally. The company offers pesticides, fungicides, herbicides, plant growth regulators, fertilizers, and microbial fertilizers. It is also involved in sale of agricu… Read more
Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) - Total Assets
Latest total assets as of September 2025: CN¥1.91 Billion CNY
Based on the latest financial reports, Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) holds total assets worth CN¥1.91 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shaanxi Meibang Pharmaceutical Group Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Shaanxi Meibang Pharmaceutical Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shaanxi Meibang Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shaanxi Meibang Pharmaceutical Group Co Ltd's total assets of CN¥1.91 Billion consist of 58.9% current assets and 41.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.4% |
| Accounts Receivable | CN¥79.76 Million | 4.3% |
| Inventory | CN¥264.71 Million | 14.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥118.48 Million | 6.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Shaanxi Meibang Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shaanxi Meibang Pharmaceutical Group Co Ltd's current assets represent 58.9% of total assets in 2024, a decrease from 83.7% in 2017.
- Cash Position: Cash and equivalents constituted 14.4% of total assets in 2024, up from 8.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 1.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 14.2% of total assets.
Shaanxi Meibang Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Shaanxi Meibang Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥49.93 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
Shaanxi Meibang Pharmaceutical Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shaanxi Meibang Pharmaceutical Group Co Ltd generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shaanxi Meibang Pharmaceutical Group Co Ltd generates $ 1.98 in net profit.
Shaanxi Meibang Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.99 | 2.86 | 1.95 |
| Quick Ratio | 1.66 | 2.38 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥524.65 Million | CN¥ 686.60 Million | CN¥ 295.43 Million |
Shaanxi Meibang Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shaanxi Meibang Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.38 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 10.0% |
| Total Assets | CN¥1.86 Billion |
| Market Capitalization | $112.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shaanxi Meibang Pharmaceutical Group Co Ltd's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shaanxi Meibang Pharmaceutical Group Co Ltd's assets grew by 10.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
The table below shows the annual total assets of Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.86 Billion | +10.05% |
| 2023-12-31 | CN¥1.69 Billion | +8.43% |
| 2022-12-31 | CN¥1.56 Billion | +6.64% |
| 2021-12-31 | CN¥1.46 Billion | +86.21% |
| 2020-12-31 | CN¥785.87 Million | +18.00% |
| 2019-12-31 | CN¥665.97 Million | +13.69% |
| 2018-12-31 | CN¥585.78 Million | +14.94% |
| 2017-12-31 | CN¥509.66 Million | -- |